×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Events
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

CLL

Brian Koffman
Patients with chronic lymphocytic leukemia are at risk for the worst of COVID-19 symptoms, but going on the cancer journey has prepared them for the pandemic.
 
Brian Koffman
Social distancing measures are keeping people apart, but that hasn't stopped some patients with CLL from finding a new sense of community.  
Brian Koffman
The COVID-19 Pandemic has changed immediate treatment for patients with chronic lymphocytic leukemia, but it is also impacting the clinical trials looking to improve the future treatment for these patients. 
CURE Staff
Dr. Richard Pazdur, director of the Food and Drug Administration’s Oncology Center of Excellence, has noted that the agency is committed to expediting oncology drug development despite the challenges posed by the COVID-19 pandemic.
 
Conor Killmurray
The Food and Drug Administration, under its global Project Orbis, approved the combination of Imbruvica and Rituxan for patients with CLL and SLL.
 
Jessica Skarzynski
Calquence (acalabrutinib) may be a safe and effective treatment option for patients with relapsed or refractory chronic lymphocytic leukemia, according to the updated phase 2 results of an ongoing study.
 
Beth Fand Incollingo
First validated prognostic score offers valuable insights for patients with chronic lymphocytic leukemia who are prescribed active surveillance.
 
Katie Kosko
Bruton tyrosine kinase (BTK) inhibitors and other new drugs are improving outcomes for patients with CLL.
 
Jessica Skarzynski
The COVID-19 pandemic's impact is being felt all throughout the cancer community, and experts from the CLL Society hosted a webinar to discuss the specific impacts of the pandemic on patients with chronic lymphocytic leukemia.
Kristie L. Kahl
Patients with relapsed or refractory CD19-positive cancers experienced complete responses with no major side effects following treatment with CAR-NK cell therapy.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×